New clinical trial design in precision medicine: discovery, development and direction

XP Duan, BD Qin, XD Jiao, K Liu, Z Wang… - Signal Transduction and …, 2024 - nature.com
In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …

EZH2-mediated development of therapeutic resistance in cancer

P Kaur, E Shankar, S Gupta - Cancer Letters, 2024 - Elsevier
Enhancer of zeste homolog 2 (EZH2) regulates gene expression and plays a definite role in
cell proliferation, apoptosis, and senescence. Overexpression of EZH2 has been found in …

[HTML][HTML] EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis

Q Zhang, Y Shi, S Liu, W Yang, H Chen, N Guo, W Sun… - Cell Reports, 2024 - cell.com
Drug resistance is the leading problem in non-small-cell lung cancer (NSCLC) therapy. The
contribution of histone methylation in mediating malignant phenotypes of NSCLC is well …

The Emerging Role of Ubiquitin-Specific Protease 36 (USP36) in Cancer and Beyond

MY Niu, YJ Liu, JJ Shi, RY Chen, S Zhang, CY Li… - Biomolecules, 2024 - mdpi.com
The balance between ubiquitination and deubiquitination is instrumental in the regulation of
protein stability and maintenance of cellular homeostasis. The deubiquitinating enzyme …

[HTML][HTML] Identification of a signature of histone modifiers in kidney renal clear cell carcinoma

Y Huang, Z Yang, Y Tang, H Chen, T Liu… - Aging (Albany …, 2024 - ncbi.nlm.nih.gov
Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with
epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic …